Zomedica Corp. · OTC:ZOMDF
Zomedica — Investor Presentation (March 2026)
30 slides from Zomedica's investor presentation, March 2026
Slide 1: Advancing Animal Health & Veterinarian Success
Advancing Animal Health & Veterinarian Success 2026 RESULTS THROUGH 4Q2025
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are Our forward-looking information is subject to a variety of risks and uncertainties and other factors that not, under any circumstances, to be construed as an offering of any
Slide 3: Zomedica's Mission
Zomedica’s Mission Bring innovative diagnostic and therapeutic technology to Veterinarians to improve the quality of care for the pet, the satisfaction of the pet parent, and the workflow, cash flow and profitability of the practice 3
Slide 4: Innovation That Enables Better Care for Your Pets
Innovation That Enables Better Care for Your Pets Significant market opportunity to address critical animal health needs Existing portfolio comprised of truly innovative technology platforms Track record of strong financial performance through focused execution Future growth trajectory self funded w
Slide 5: Trends in Animal Health Have Set the Stage for a Huge Opportunity
Trends in Animal Health Have Set the Stage for a Huge Opportunity Pet Ownership is Pet Owners Are Increasing Getting Younger >23M ~50% U.S households who % Gen-Z U.S dog-owning adopted a pet during households with one or more $62B the pandemic1 dogs under the age of two2 The Human-Animal Bond is Inc
Slide 6: Delivering Product Innovation
Delivering Product Innovation 6
Slide 7: Our Portfolio is Well-Positioned to Address Critical Animal Health Needs
Our Portfolio is Well-Positioned to Address Critical Animal Health Needs By Delivering Innovation to Veterinarians and Pet Parents, Therapeutic Devices We Seek to Improve Accelerate Healing, Reduce Pain The quality of care of the pet The satisfaction of the pet parent ZOM•Dx Veterinarian workflow Cu
Slide 8: PulseVet Shock Wave System
THERAPEUTIC DEVICES The Global Leader in Shock Wave Technology PulseVet® Shock Clinically proven to enhance the quality & speed of healing in various musculoskeletal indications, from ligament and tendon injuries to osteoarthritis, lick granulomas, LS disease, Wave System and non-union fractures Tre
Slide 9: Assisi Devices
THERAPEUTIC DEVICES Assisi tPEMF therapy Complements PulseVet Shock Wave therapy at Home Assisi® Devices Assisi Loop® & Assisi Loop Lounge® Recently Launched Line Extensions • Sold for pain and • DentaLoop® device inflammation from OA, indicated for gum disease and wound healing and pain from extrac
Slide 10: VETIGEL Hemostatic Gel
VETIGEL hemostatic gel stops bleeding in seconds – THERAPEUTIC DEVICES reducing blood loss and saving O.R. & anesthesia time VETIGEL® Controls bleeding faster to save time Reduces blood loss for better outcomes Hemostatic Gel In a comparative study, VETIGEL® was found to stop severe bleeding in soft
Slide 11: TRUVIEW AI Microscope & TelePathology Platform
ZOM•Dx TRUVIEW AI Digital Cytology Platform & Pathology Services Microscope & Innovative digital imaging system with LiquiView liquid lens optics provide best-in-class visualization with TRUprep fully automated slide prep TelePathology Platform First-in-class automated Reduces slide prep errors slid
Slide 12: TRUFORMA Platform
ZOM•Dx Reference Lab Accuracy at the Point of Care TRUFORMA® with TRUFORMA Diagnostic Platform Platform Disposable cartridge preloaded with reagents Timely and accurate results Minimizes sample prep & Supports practitioner’s simplifies workflow ability to diagnose with confidence Compact instrument
Slide 13: VETGuardian PLUS Pet Monitoring System
ZOM•Dx VETGuardian® Wireless Remote Monitoring System PLUS Pet Ensure vulnerable pets are efficiently monitored 24-hour no touch vital signs monitoring capability Monitoring System provides improved care for pet patients, enhanced workflow and new revenue stream for practice 24-hour Zero Touch Vital
Slide 14: Zomedica Has the Opportunity to Service A Multi-Billion Dollar Market
Zomedica Has the Opportunity to Service A Multi-Billion Dollar Market U.S. Customer Base U.S. Total Annual Serviceable Market Recurring Revenue Opportunities 4,450 $500M $1,500M $290M $150M $40M $270M $2.7B Equine or Mixed Total Annual Market1 Practices Recurring Annual Revenue Range: $650 - $24,000
Slide 15: Producing Compelling Results
Producing Compelling Results 15
Slide 16: Zomedica Has Driven Sustained Growth With a Strong Financial Profile
Zomedica Has Driven Sustained Growth With a Strong Financial Profile Financial Strength 17% 2025YoY Revenue Growth1 2025: $32.0 million 2024: $27.3 million 67-69% 2023: $25.2 million Gross Margins2 2022: $18.9 million 2021: $4.1 million $4-5M Historic operating burn / quarter3 TRUFORMA® Launch Pulse
Slide 17: Pathway to Delivering Accelerating, Profitable Growth
Pathway to Delivering Accelerating, Profitable Growth 17
Slide 18: Pathway to Delivering Accelerating, Profitable Growth
Pathway to Delivering Accelerating, Profitable Growth 1. Leveraging Optimized Commercial Infrastructure to Drive Adoption 2. Expanding our Innovative Product Portfolio 3. Executing Disciplined Business Development and M&A Strategy 4. Driving Leverage Through Operational Efficiencies 18
Slide 19: 1. Leveraging Optimized Commercial Team to Drive Adoption
1. Leveraging Optimized Commercial Team to Drive Adoption Direct Salesforce Distribution Networks Canada & Japan Europe Australia Middle East South America Executing initiatives to drive accelerated adoption and utilization of Zomedica’s Diversified International Sales Infrastructure portfolio by Ve
Slide 20: 2. Expanding our Innovative Product Portfolio
2. Expanding our Innovative Product Portfolio Therapeutic Devices ZOM•Dx New Indications New Assays PulseVet®, Assisi® platforms TRUFORMA® platform Supporting clinical studies to identify Continue to add new high-value assays new technology applications • Focused on reproductive, cardiac, endocrine
Slide 21: Direct Sales Channel Driving Incremental Gains
SALES Direct Sales Channel Driving Incremental Gains Targeting key Veterinarian practices by segment Using distribution relationships to better access new customers PulseVet® system: Leveraging the exceptional acceptance in the equine market to drive adoption in small animal space TRUFORMA® platform
Slide 22: 3. Executing Disciplined Business Development and M&A Activity
3. Executing Disciplined Business Development and M&A Activity Zomedica’s continued investment in external innovation will accelerate our growth, and path to profitability Over the past three years, Zomedica has Leveraging our extensive been driving a three-part growth strategy networks in the Anima
Slide 23: 3. Executing Disciplined Business Development and M&A Activity
3. Executing Disciplined Business Development and M&A Activity 2021 2022 2023 2024 2025 2026 VETIGEL Product Line Launch TRUVIEW TRUVIEW AI Product Line Launch Product Line Launch TRUVIEW Distribution Agreement w/ Moichor VETGuardian VETGuardian PLUS Product Line Launch Product Line Launch Assisi Pr
Slide 24: Innovation Worthy of Investment
Innovation Worthy of Investment Track record of identifying and efficiently acquiring We continue to seek differentiated products that highly differentiated, high potential technologies share these attributes: that elevate the standard of care in Animal Health • Highly differentiated clinically – el
Slide 25: 4. Driving Leverage Through Operational Efficiencies
4. Driving Leverage Through Operational Efficiencies Key Enablers of Improving Operational Efficiency Ability to scale Roswell facility production by 5x to meet future growth targets Full integration of Qorvo Biotechnologies’ R&D and manufacturing facility Through prior New, highly automated manufac
Slide 26: 4. Driving Leverage Through Operational Efficiencies
4. Driving Leverage Through Operational Efficiencies The Next Phase of Product Innovation to Drive Increased Utilization Zomedica Global Zomedica Global Manufacturing & Manufacturing & Distribution Distribution Center, North Center, South Acquired in Plymouth, Established in Roswell, MN in October 2
Slide 27: Innovation That Enables Better Care for Your Pets
Innovation That Enables Better Care for Your Pets Significant market opportunity to address critical animal health needs Existing portfolio comprised of truly innovative technology platforms Track record of strong financial performance through focused execution Future growth trajectory self funded w
Slide 28: Supporting Improved Pet Care Through Digital Technology Solutions
R&D Supporting Improved Pet Care Through A Hub for Clinical & Customer Experiences Digital Technology Solutions Allows our veterinary partners to engage with us beyond just test results A stage for delivering clinical decision support myZomedica® An eCommerce platform for streamlining the reordering
Slide 29: Driving Sustained Growth With a Strong Financial Profile
Driving Sustained Growth With a Strong Financial Profile Annual Revenue ($M) Gross Margin $32.0 $27.3 +17% 73% 74% $25.2 71% 70% 71% 72% 70% +8% 68% 67% 69% 69% 68% 67% 67% 69% $18.9 +33% 66% +361% Historical margins ~70% with slight decrease in certain quarters due to mix of new products and acquis
Slide 30: Advancing Animal Health & Veterinarian Success
Advancing Animal Health & Veterinarian Success 30